Neuca

Neuca Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Neuca (NEU.WA) as of Oct 21, 2026 is 319.15 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 40.99 % — a change of 678.56% (higher).

Cash Conversion

319.15 %

YoY

678.56%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Neuca is 2025 319.15 % . Cash Conversion Rate (OCF/Net Income) of Neuca was 2024 40.99 % . It decreases by 678.56% higher compared to the previous year.

The Neuca Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
124.08 PLN
Jan 1, 2019
171.90 PLN
Jan 1, 2020
228.98 PLN
Jan 1, 2021
199.26 PLN
Jan 1, 2022
244.78 PLN
Jan 1, 2023
197.08 PLN
Jan 1, 2024
40.99 PLN
Jan 1, 2025
319.15 PLN
The Neuca Cash Conversion history
YEARCash ConversionYoY
319.15 %+678.56%
40.99 %-79.20%
197.08 %-19.49%
244.78 %+22.85%
199.26 %-12.98%
228.98 %+33.21%
171.90 %+38.54%
124.08 %-3.71%
128.85 %-17.76%
156.68 %-12.04%
178.12 %-18.16%
217.64 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neuca Stock analysis

What does Neuca do? NEUCA SA generates revenue through the wholesale distribution of pharmaceutical products to pharmacies, leveraging its extensive network in the health market. The company also produces and sells its own branded drugs, supplements, and cosmetics, while offering clinical trials, telemedicine services, and IT solutions tailored for healthcare providers. Its e-commerce platform further supports the healthcare industry by enabling digital transactions for medical products and services. The primary buyers include pharmacies, healthcare institutions, and consumers seeking health-related products through online channels. NEUCA SA's business model integrates multiple revenue streams within the health sector, with a focus on both physical and digital distribution. The firm's own-brand products, such as pharmaceuticals and cosmetics, are sold directly to end-users and retail partners, while its IT solutions and telemedicine services target healthcare organizations. Clinical trials represent another key segment, attracting partnerships with research institutions and pharmaceutical firms. The company's operational scope spans from production to distribution, ensuring a comprehensive approach to healthcare market needs. The company's revenue is driven by its diversified portfolio, including drug distribution, branded product sales, and specialized services like telemedicine and clinical trials. Pharmacies remain the core customer segment for its wholesale operations, while e-commerce and IT solutions cater to a broader audience of healthcare providers and consumers. NEUCA SA's strategic positioning in the health market allows it to capitalize on multiple growth areas without relying on a single revenue source. Neuca is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuca stock

Cash Conversion Rate (OCF/Net Income) of Neuca is 319.15 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Neuca changed from 40.99 % to 319.15 %, representing a 678.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Neuca since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Neuca with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Neuca

All Key Metrics — Neuca